Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion

Zambruno, Giovanna; Borradori, Luca (2008). Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. Journal of Investigative Dermatology, 128(12), pp. 2745-7. New York, N.Y.: Nature Publishing 10.1038/jid.2008.330

Full text not available from this repository. (Request a copy)

The anti-CD20 mAb rituximab, first approved for use in B-cell malignancies, is increasingly used to treat a variety of autoimmune diseases. Two studies in this issue investigate the effects of rituximab in pemphigus. Rituximab induces not only a depletion of all B cells and a decline of antidesmoglein autoantibodies but also a decrease in desmoglein-specific T cells. Furthermore, B-cell populations recovered after treatment were modified. These novel aspects may contribute to the clinical responses observed in patients.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Borradori, Luca

ISSN:

0022-202X

ISBN:

18997839

Publisher:

Nature Publishing

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:04

Last Modified:

04 May 2014 23:19

Publisher DOI:

10.1038/jid.2008.330

PubMed ID:

18997839

Web of Science ID:

000261062500001

URI:

https://boris.unibe.ch/id/eprint/27642 (FactScience: 109768)

Actions (login required)

Edit item Edit item
Provide Feedback